In what may well be the first drug targeted at African Americans, NitroMed is attempting to pursue both study and marketing aimed at what might be a hugely controversial heart failure treatment. Minneapolis Star Tribune breaks this story.
Labels: BiDil, heart failure, NitroMed, targetting drugs
